Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Pharmacological approaches for targeting cystic fibrosis nonsense mutations 2020
2020 A regulated NMD mouse model supports NMD inhibition as a viable therapeutic option to treat genetic diseases 2020
2020 Finding sense in the context: Ribosomal profiling has shed new light on how ribosomes can ignore stop codons in messenger RNA.  eLife.  9. 2020
2020 A regulated NMD mouse model supports NMD inhibition as a viable therapeutic option to treat genetic diseases. 2020
2017 Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.  Human Molecular Genetics.  26:3116-3129. 2017
2016 Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases..  Diseases.  4. 2016
2016 Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations.  American Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
2014 Therapeutics based on stop codon readthrough.  Annual Review of Genomics and Human Genetics.  15:371-394. 2014
2012 Suppression of premature termination codons as a therapeutic approach.  Critical Reviews in Biochemistry and Molecular Biology.  47:444-463. 2012
2011 Enhancement of alveolar epithelial sodium channel activity with decreased cystic fibrosis transmembrane conductance regulator expression in mouse lung 2011
2009 Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis Mouse model.  Journal of Biological Chemistry.  284:6885-6892. 2009
2006 Eukaryotic release factor 1 phosphorylation by CK2 protein kinase is dynamic but has little effect on the efficiency of translation termination in Saccharomyces cerevisiae.  Eukaryotic Cell.  5:1378-1387. 2006
2006 Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model 2006
2006 Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease [2].  Journal of Investigative Dermatology.  126:229-231. 2006
2005 Pharmacological suppression of premature stop mutations that cause genetic diseases 2005
2002 Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene 2002
2002 Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAS in a mammalian translation system 2002
2001 Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.  Human Molecular Genetics.  10:291-299. 2001
1999 Diffusion-controlled crystallization apparatus for microgravity (DCAM): flight and ground-based applications.  Journal of Crystal Growth.  196:602-609. 1999
1999 Lower dimer impurity incorporation may result in higher perfection of HEWL crystals grown in microgravity, a case study..  Journal of Protein Crystal Growth.  196:623-637. 1999
1999 PCAM: a multi-user facility-based protein crystallization apparatus for microgravity.  Journal of Crystal Growth.  196:610-622. 1999
Ataluren Suppresses a Premature Termination Codon in an MPS I-H Mouse

Chapter

Year Title Altmetric
2010 Recoding Therapies for Genetic Diseases 2010
2005 Therapies of Nonsense-Associated Diseases.  121-136. 2005

Research Overview

  • translation
    translation termination
    mRNA stability
    mRNA turnover
    rare or orphan diseases
    mucopolysaccharidosis I-Hurler (MPS I-H)
    lysosomal storage disease
    cystic fibrosis

    • Principal Investigator On

    Investigator On

    Education And Training

  • UAB Microbiology, Postdoctoral Fellowship
  • Bachelor of Science or Mathematics in Chemistry, University of Alabama at Birmingham 1990

    • Full Name

  • Kim Keeling